{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:47:52Z","timestamp":1791233272565,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,4,1]]},"DOI":"10.1093\/jac\/dkl022","type":"journal-article","created":{"date-parts":[[2006,2,8]],"date-time":"2006-02-08T02:41:30Z","timestamp":1139366490000},"page":"705-708","source":"Crossref","is-referenced-by-count":169,"title":["Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis"],"prefix":"10.1093","volume":"57","author":[{"given":"Michel","family":"Laverdi\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Lalonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Guy","family":"Baril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Perlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,2,7]]},"reference":[{"key":"key\n\t\t\t\t20171012145531_B1","doi-asserted-by":"crossref","unstructured":"De Wet N, Llanos-Cuenta A, Suleiman J et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared to fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis2004; 39: 842\u20139.","DOI":"10.1086\/423377"},{"key":"key\n\t\t\t\t20171012145531_B2","doi-asserted-by":"crossref","unstructured":"Krause D, Simjee AE, Van Rensburg C et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis2004; 39: 770\u20135.","DOI":"10.1086\/423378"},{"key":"key\n\t\t\t\t20171012145531_B3","doi-asserted-by":"crossref","unstructured":"Villanueva A, Arathoon EG, Gotuzzo E et al. A randomized, double-blind trial of caspofungin versus amphotericin B for the treatment of candidal esophagitis. Clin Infect Dis2001; 33: 1529\u201335.","DOI":"10.1086\/323401"},{"key":"key\n\t\t\t\t20171012145531_B4","doi-asserted-by":"crossref","unstructured":"Moudgal V, Little T, Boikov D et al. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother2005; 49: 767\u20139.","DOI":"10.1128\/AAC.49.2.767-769.2005"},{"key":"key\n\t\t\t\t20171012145531_B5","doi-asserted-by":"crossref","unstructured":"Pfaller MA, Messer SA, Boyken L et al. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J Clin Microbiol2004; 42: 3117\u201319.","DOI":"10.1128\/JCM.42.7.3117-3119.2004"},{"key":"key\n\t\t\t\t20171012145531_B6","doi-asserted-by":"crossref","unstructured":"Ostrosky-Zeichner L, Rex J, Pappas P et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother2003; 47: 3149\u201354.","DOI":"10.1128\/AAC.47.10.3149-3154.2003"},{"key":"key\n\t\t\t\t20171012145531_B7","doi-asserted-by":"crossref","unstructured":"Laverdiere M, Hoban D, Restieri C et al. In vitro activity of three new azoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother2002; 50: 119\u201323.","DOI":"10.1093\/jac\/dkf074"},{"key":"key\n\t\t\t\t20171012145531_B8","doi-asserted-by":"crossref","unstructured":"Hernandez S, Lopez-Ribot JL, Najvar LK et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testings of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother2004; 48: 1382\u20133.","DOI":"10.1128\/AAC.48.4.1382-1383.2004"},{"key":"key\n\t\t\t\t20171012145531_B9","unstructured":"National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A. NCCLS, Wayne, PA, USA, 1997."},{"key":"key\n\t\t\t\t20171012145531_B10","doi-asserted-by":"crossref","unstructured":"Odds FC, Motyl M, Andrade R et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol2004: 42; 475\u201382.","DOI":"10.1128\/JCM.42.8.3475-3482.2004"},{"key":"key\n\t\t\t\t20171012145531_B11","doi-asserted-by":"crossref","unstructured":"Park S, Kelly R, Nielsen Kahn J et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother2005; 49: 3264\u201373.","DOI":"10.1128\/AAC.49.8.3264-3273.2005"},{"key":"key\n\t\t\t\t20171012145531_B12","doi-asserted-by":"crossref","unstructured":"Bougnoux ME, Morand D, d'Enfert C. Usefulness of multilocus sequence typing for characterization of clinical isolates of Candida albicans. J Clin Microbiol2002; 40: 1290\u20137.","DOI":"10.1128\/JCM.40.4.1290-1297.2002"},{"key":"key\n\t\t\t\t20171012145531_B13","doi-asserted-by":"crossref","unstructured":"Bougnoux ME, Tavanti A, Bouchier C et al. Collaborative consensus for optimized multilocus sequence typing of Candida albicans. J Clin Microbiol2003; 41: 5265\u20136.","DOI":"10.1128\/JCM.41.11.5265-5266.2003"},{"key":"key\n\t\t\t\t20171012145531_B14","doi-asserted-by":"crossref","unstructured":"Hiemenz J, Cagnoni P, Simpson D et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with flucomazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother2005; 49: 1331\u20136.","DOI":"10.1128\/AAC.49.4.1331-1336.2005"},{"key":"key\n\t\t\t\t20171012145531_B15","doi-asserted-by":"crossref","unstructured":"Jarvis B, Figgitt D, Scott L. Micafungin. Drugs2004; 64: 969\u201382.","DOI":"10.2165\/00003495-200464090-00004"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/57\/4\/705\/1943218\/dkl022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T19:14:05Z","timestamp":1507835645000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/57\/4\/705\/669412\/Progressive-loss-of-echinocandin-activity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,7]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2006,2,7]]},"published-print":{"date-parts":[[2006,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkl022","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,4]]},"published":{"date-parts":[[2006,2,7]]}}}